Paul M. Coplan SC.D

faculty photo
Adjunct Assistant Professor of Epidemiology in Biostatistics and Epidemiology
Department: Biostatistics and Epidemiology
Graduate Group Affiliations

Contact information
The International Partnership for Microbicides, Inc.
1010 Wayne Avenue
Suite 1450
Silver Spring, MD 20910
Office: (301) 608-2221
Fax: (301) 608-2241
Education:
Other (?)
?, 0.
Permanent link
 

Description of Research Expertise

Research Interests:

Adherence, complementary/alternative medicine, genetic Epi, infectious diseases, pain, causal inference, diagnostic testing, repeated measures.

Dr. Coplan is responsible for clinical trials, regulatory strategy, and international clinical site development at the International Partnership for Microbicides (IPM). Dr. Coplan is also an adjunct faculty member of the Department of Clinical Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine. Prior to joining IPM, he worked at Merck Research Laboratories for nine years as Associate Director in Worldwide Regulatory Affairs and Associate Director in Epidemiology. He worked on the licensure and post licensure of numerous products including inidinavir, efavirenz (STOCRIN), varicella vaccine, hepatitis A vaccine, hemophilus influenzae type b vaccine, and two combination vaccines. He worked on the development of four new vaccines (HIV, HPV, shingles, and rotavirus vaccines) and was the Merck Regulatory Liaison for HIV and Shingles vaccine programs. Prior to joining Merck, Paul worked with adolescents in Nigeria, as a developer of village health worker training programs and primary health care programs in rural Zimbabwe for Oxfam, and as a bench scientist developing novel antimicrobials to treat leishmaniasis in collaboration with the Walter Reed Institute. He received a Doctorate of Science in Epidemiology from Harvard University, a Masters of Business Administration from Wharton Business School at the University of Pennsylvania, a dual Masters of Science degree in Public Health and Nutrition from the University of Massachusetts, and a Bachelor of Science Honors degree in Biochemistry and Physiology from the University of Witwatersrand, South Africa.

Selected Publications

Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain. 5(6): 344-56, August 2004.

Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ; AIDS Clinical Trials Group 320 Study Team: Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis. 39(3): 426-33 (Epub July 19, 2004), August 1 2004.

Coplan PM, Mitchnick M, Rosenberg ZF: Public health. Regulatory challenges in microbicide development. Science 304(5679): 1911-2, June 25 2004.

Rojas C, Coplan PM, Rhodes T, Robertson MN, DiNubile MJ, Guess HA: Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. Pharmacoepidemiol Drug Saf. 12(5): 361-9, Jul-Aug 2003.

Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, Xu Y, DiNubile MJ.: Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses. 19(6): 449-55, June 2003.

Fife KH, Coplan PM, Jansen KU, DiCello AC, Brown DR, Rojas C, Su L: Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men. Sex Transm Dis. 30(3): 246-8, March 2003.

Coplan PM, Nikas AA, Leavitt RY, Doll L, Nessly ML, DiNubile MJ, Guess HA.: Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. AIDS 15(12): 1584-6, August 17 2001.

Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM. : Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med. 155(4): 455-61, April 2001.

Markey P, Krause V, Boslego JW, Coplan PM, Dargan JM, Kaplan KM.: The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high-risk population measured using immunization register data. Epidemiol Infect. 126(1): 31-6, February 2001.

Pellissier JM, Coplan PM, Jackson LA, May JE: The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 6(9): 1038-44, September 2000.

back to top
Last updated: 10/07/2004
The Trustees of the University of Pennsylvania